ClinicalTrials.gg
TerminatedNCT05603572Updated Oct 27, 2026

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

A Phase 1/2 interventional study of KAT-101 and KAT-201 in Hepatocellular Carcinoma and Fibrolamellar Carcinoma, sponsored by Primocure Pharma. Terminated at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Primocure Pharma · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
discontinued enrollment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 10 months ago, and no results have been posted to the registry.
Updated Oct 27, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.

Enrollment
252nd of 255
1 · median 87
Started
2022
with 16 others
Phase 1/2
28 of 298
6 open now
Registered
234th of 298
by date

Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 252nd largest by enrollment of the 255 interventional ones that give a count, is one of 17 that started in 2022, is one of 28 in phase 1/2, and was the 234th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, or all of them as a file.
02

Study summary

NLP-KAT-101 is a Phase 1/2a dose escalation and expansion study to investigate the safety, tolerability, PK, and preliminary efficacy of oral + intratumoral (IT) KAT in subjects with HCC.

Read the detailed description

Phase 1 will identify the optimal dose for oral alone, IT alone and the recommended Phase 2 dose (RP2D) dose for oral + IT together. Once the RP2D is identified, additional subjects will be enrolled into Phase 2a (dose-expansion) to further investigate the efficacy and safety of oral + IT KAT at the RP2D.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Fibrolamellar Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed HCC not amenable to surgical resection or curative-intent locoregional ablative treatments and who are not eligible for liver transplantation.
  • Systemic treatment-naive for unresectable locally advanced or HCC. In addition, have progressed on, refused or were intolerant to sorafenib, lenvatinib, or atezolizumab in combination with bevacizumab. A maximum of 2 (including chemotherapy or targeted therapy, not including locoregional therapy) will be allowed.
  • At least one based on 1.1
  • (ECOG) performance status 0-2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Prior to the first administration of the study treatment:

    1. Major surgery within 28 days
    2. Radiotherapy within 14 days including palliative radiation
    3. Use of (except for topical agents) within 14 days
    4. Chemotherapy within 3 weeks (6 weeks for nitrosourea compounds)
    5. Prior treatment with biologic agents, including hormone therapy, within the last 3 weeks, or at least 5 half-lives, whichever is shorter
    6. Tumor infiltration in the portal vein, hepatic veins or inferior vena cava that completely blocks circulation in liver
    7. Treatment with another product within 4 weeks prior to screening or for which 5 half-lives have not elapsed, whichever is longer
    8. Uncontrolled central nervous system (CNS)
  • Any abnormal intestinal findings that may interfere with the investigational product
  • Severe cardiac disorders or subjects with comorbidities of other serious internal disorders on investigator's judgment
  • > 450 msec or congenital long QT syndrome
  • Suspected serious infectious diseases, intestinal paralysis, bowel obstruction, interstitial pneumonia, or pulmonary fibrosis
  • Serious underlying medical or psychiatric condition, dementia or altered mental status that would impair the ability to understand , contraindicate participation in the study or confound the results of the study
  • Known (HIV) infection or chronic or active virus (HBV) virus (HCV). Subjects with HCV who have a documented cure (undetectable HCV ribonucleic acid (RNA) 24 weeks after the end of treatment) may be enrolled.
  • Severe physical or mental trauma that results from injury or a wound(s).
  • Any condition or non-removable device for MRI examination
  • Pregnant women or nursing mothers.
  • Women of (WOCBP) who are unwilling to use a medically acceptable method of during the study until 185 days after the last dose of study treatment
  • Men with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the study until 95 days after the last dose of study treatment.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Oral experimental arm

    Oral administration (KAT-101) taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Each cycle is 28 days. Treatment will continue for up to 12 cycles until progressive disease (PD), unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.

    Drug: KAT-101

  • Experimental
    IT experimental arm

    IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or computed tomography (CT) guidance once a week (on Day 1 weekly). Each cycle is 28 days. Treatment will continue for up to 2 cycles until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.

    Drug: KAT-201

  • Experimental
    Oral + IT experimental arm

    Once optimal oral and IT dose are determined, oral + IT will be administered as follows: oral administration (KAT-101) will be taken once per day for 4 consecutive days out of 7 (4 days on / 3 days off weekly). Treatment will continue for up to 12 cycles (each cycle 28 days). IT administration (KAT-201) will be injected via percutaneous IT injection with ultrasound and/or CT guidance once a week (on Day 1 weekly). Treatment will continue for up to 2 cycles (each cycle 28 days) until PD, unacceptable toxicity, or any reason for discontinuing its administration, whichever occurs first.

    Drug: KAT-101 · Drug: KAT-201

Interventions

  • DrugKAT-101

    oral dosage form

  • DrugKAT-201

    IT dosage form

06

What researchers measure

Primary outcomes

  1. To determine the Recommended Phase 2 Dose (RP2D) for oral + IT administration

    RP2D is defined as the dose at which dose escalation (oral + IT) ceases

    Time frame: 24 months

Secondary outcomes

  1. To evaluate the safety and tolerability of KAT (oral, IT, and oral + IT) in subjects with HCC

    Measured as the number of AEs per CTCAE and changes in laboratory values compared to baseline.

    Time frame: 54 months

  2. To evaluate the preliminary anti-tumor activity of KAT for oral + IT administration

    Overall response rate (ORR) is defined as the proportion of subjects with a best overall response (BOR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and/or mRECIST; disease control rate (DCR), defined as the proportion of subjects with a BOR of CR, PR, or stable disease (SD); duration of response (DOR), defined as the length of time from the time of response (CR or PR) to the time of PD or death; progression-free survival (PFS), defined as the time from the date of treatment initiation to PD or death; overall survival (OS), defined as the length of time from the date of treatment initiation to death from any cause.

    Time frame: 54 months

  3. To assess maximum concentration (Cmax) of KAT (oral and oral + IT)

    Blood samples will be drawn to determine Cmax of KAT

    Time frame: 54 months

  4. To assess median time to the maximum drug concentration (Tmax) of KAT (oral and oral + IT)

    Blood samples will be drawn to determine Tmax of KAT

    Time frame: 54 months

  5. To assess half lives (T1/2) of KAT (oral and oral + IT)

    Blood samples will be drawn to determine T1/2 of KAT

    Time frame: 54 months

  6. To assess area under the curve (AUC) of KAT (oral and oral + IT)

    Blood samples will be drawn to determine AUC of KAT

    Time frame: 54 months

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, 06351, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2022 to primary completion in Dec 2022, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Nov 2027 → Dec 2022 and completion Nov 2027 → Dec 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2022
First posted
Nov 2, 2022
StartActual
Nov 1, 2022
Primary completionActual
Dec 26, 2022was Nov 2027
CompletionActual
Dec 26, 2022was Nov 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Terminated discontinued enrollment
changed Oct 27, 2026
Sites
2 sites removed
Show 2 removed
  • Kyungpook National University Hospital · Daegu, Korea, Republic of
  • Seoul National University Hospital · Seoul, Korea, Republic of
Oct 27, 2026
Primary completion
Nov 2027→Dec 26, 2022 (actual)
Oct 27, 2026
Study completion
Nov 2027→Dec 26, 2022 (actual)
Oct 27, 2026
Enrollment
148 (estimated)→1 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Suspended→Terminated
    Why stopped discontinued enrollment
    2 sites removed
    Show 2 removed
    • Kyungpook National University Hospital · Daegu, Korea, Republic of
    • Seoul National University Hospital · Seoul, Korea, Republic of
    Primary completion Nov 2027→Dec 26, 2022 (now actual)
    Study completion Nov 2027→Dec 26, 2022 (now actual)
    Enrollment 148 (estimated)→1 (actual)
    + 4 other changes: verification date, registry dates, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05603572
Lead sponsor
Primocure Pharma
Responsible party
Sponsor
First posted
Nov 2, 2022
Start date
Nov 1, 2022
Primary completion
Dec 26, 2022
Completion
Dec 26, 2022
Last update
Oct 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion